ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 ANS Annual Conference
May 31–June 3, 2026
Denver, CO|Sheraton Denver
Latest Magazine Issues
Jan 2026
Jul 2025
Latest Journal Issues
Nuclear Science and Engineering
February 2026
Nuclear Technology
January 2026
Fusion Science and Technology
November 2025
Latest News
Jeff Place on INPO’s strategy for industry growth
As executive vice president for industry strategy at the Institute of Nuclear Power Operations, Jeff Place leads INPO’s industry-facing work, engaging directly with chief nuclear officers.
George A. Miller, Jr., Nolan E. Hertel, Bernard W. Wehring, John L. Horton
Nuclear Technology | Volume 103 | Number 3 | September 1993 | Pages 320-331
Technical Paper | Radiation Biology and Medicine | doi.org/10.13182/NT93-A34855
Articles are hosted by Taylor and Francis Online.
A computer study of the dose distribution for gadolinium neutron capture therapy is carried out to determine its feasibility. Gadolinium is a potential neutron capture therapy (NCT) agent that produces gamma radiation, conversion electrons, and Auger electrons. The dose distribution from neutrons, neutron-induced gammas, and the reaction products from neutron capture in gadolinium were modeled using the Los Alamos National Laboratory Monte Carlo neutron photon computer code. The results of these calculations are that gadolinium has promise as an NCT agent. Using two parallel opposed epithermal neutron beams for a tumor at an 8.0-cm depth with a gadolinium loading of 100 µg/g, the tumor to peak normal tissue dose was determined to be 1.48.